Apimeds Pharmaceuticals US, Inc
APUS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $25 | $25 | $25 | $25 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $0 | $1 | $0 |
| Enterprise Value | $26 | $25 | $26 | $26 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| Net Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.11 | -0.061 | -0.053 | -0.081 |
| % Growth | -79.4% | -16.3% | 34.8% | – |
| Operating Cash Flow | -$1 | -$1 | -$0 | -$1 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1 | -$1 | -$0 | -$1 |